Maravai Lifesciences Holdings (MRVI) Cash from Financing Activities (2020 - 2026)

Maravai Lifesciences Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$55.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 1027.06% year-over-year to -$55.2 million; the TTM figure through Mar 2026 stood at -$66.8 million (up 72.16% YoY), while the FY2025 annual figure was -$16.5 million, up 93.0% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$55.2 million, down from -$1.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $809000.0 in Q3 2024, with the low at -$236.2 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$8.2 million (2025), against an average of -$32.7 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities soared 102.09% in 2023, then tumbled 50352.98% in 2024.
• Maravai Lifesciences Holdings' Cash from Financing Activities stood at -$66.1 million in 2022, then surged by 100.71% to $470000.0 in 2023, then sank by 50352.98% to -$236.2 million in 2024, then soared by 99.23% to -$1.8 million in 2025, then plunged by 2941.08% to -$55.2 million in 2026.
• Business Quant data shows MRVI's Cash from Financing Activities at -$55.2 million in Q1 2026, -$1.8 million in Q4 2025, and -$8.2 million in Q3 2025.